 Navidea Biopharmaceuticals, Inc. NYSE American: NAVB Navidea or the Company, a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce that the Company has regained the commercialization and distribution rights in Europe for LYMPHOSEEK technetium Tc99m tilmanocept injection from Norgine B.V. Norgine. Navidea and Norgine have decided, by mutual agreement, to end the existing license agreement Agreement between the two companies. 